Victory Capital Management Inc. Boosts Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Victory Capital Management Inc. boosted its position in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 39.5% during the 3rd quarter, HoldingsChannel reports. The firm owned 122,228 shares of the company’s stock after purchasing an additional 34,589 shares during the period. Victory Capital Management Inc.’s holdings in Pacira BioSciences were worth $1,840,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC increased its position in Pacira BioSciences by 229.6% in the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after buying an additional 932 shares in the last quarter. Park Place Capital Corp purchased a new position in Pacira BioSciences during the second quarter valued at approximately $46,000. Innealta Capital LLC bought a new position in shares of Pacira BioSciences in the second quarter worth approximately $50,000. nVerses Capital LLC increased its stake in shares of Pacira BioSciences by 800.0% in the second quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after purchasing an additional 1,600 shares in the last quarter. Finally, Natixis bought a new stake in shares of Pacira BioSciences during the 1st quarter valued at $95,000. 99.73% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on PCRX. StockNews.com lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, August 12th. Royal Bank of Canada increased their target price on Pacira BioSciences from $15.00 to $16.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. HC Wainwright lowered their price target on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating on the stock in a report on Monday, August 12th. JPMorgan Chase & Co. reaffirmed an “underweight” rating and set a $10.00 price objective (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Finally, Truist Financial lowered shares of Pacira BioSciences from a “buy” rating to a “sell” rating and dropped their target price for the stock from $30.00 to $8.00 in a research report on Tuesday, August 13th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Pacira BioSciences currently has an average rating of “Hold” and an average target price of $23.50.

Pacira BioSciences Stock Up 1.0 %

Shares of NASDAQ PCRX opened at $17.55 on Monday. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $35.95. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $810.28 million, a price-to-earnings ratio of -8.65 and a beta of 0.82. The firm’s 50-day moving average price is $16.21 and its 200-day moving average price is $20.30.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.